SCCM Resource Library-Ketamine's Growing Role in Opioid-Sparing Analgesic Initiatives

Ketamine's Growing Role in Opioid-Sparing Analgesic Initiatives

Video Transcription

Video Summary

Luma Sukkar, a clinical pharmacist in the Surgical and Liver Transplant ICU, discusses the use of ketamine in opioid-sparing analgesic initiatives. Ketamine, an FDA-approved drug for anesthesia, has off-label uses in pain management. It inhibits the NMDA receptor, reducing the propagation of pain signals. Studies show that ketamine reduces opioid requirements and pain scores in the post-operative setting. Dosing ranges from 0.1 to 0.5 mg/kg/hour, with no major adverse effects noted. However, additional randomized controlled trials are needed to establish its role, safety profile, and optimal dosing. Institutional protocols should be developed to guide its use.

Asset Subtitle

Pharmacology, 2023

Asset Caption

Type: one-hour concurrent | Innovative Approaches to Acute Pain Management in Critically Ill Patients (SessionID 1144410)

Meta Tag

Content Type Presentation

Knowledge Area Pharmacology

Membership Level Professional

Membership Level Select

Tag Analgesia and Sedation

Year 2023

Keywords

Luma Sukkar

ketamine

opioid-sparing analgesic

NMDA receptor

pain management

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.